Optimized protocol to detect protein UFMylation in cells and in vitro via immunoblotting

Ubiquitin-fold modifier 1 (UFM1) system is a recently identified ubiquitin-like modification with essential biological functions. Similar to ubiquitination, the covalent conjugation of UFM1 (UFMylation) to target proteins involves a three-step enzymatic cascade catalyzed sequentially by UFM1-activating enzyme 5 (UBA5, E1), UFM1-conjugating enzyme 1 (UCF1, E2), and UFM1-specific ligase 1 (UFL1, E3). Here, we provide an optimized protocol adapted to previously reported methods for detecting the UFMylation of target protein in human cells and in vitro assays, respectively, with high reliability and reproducibility.
Protocol

Optimized protocol to detect protein UFMylation in cells and in vitro via immunoblotting

Junzhi Zhou,1,2 Qian Liang,1 Maogong Dong,1 Xiaohe Ma,1 Yaqi Jin,1 Di Guan,1 Jiang Liu,1 Miao Wang,1 and Yu-sheng Cong1,3,*

1Key Laboratory of Aging and Cancer Biology of Zhejiang Province, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou, China
2Technical contact
3Lead contact
*Correspondence: yscong@hznu.edu.cn
https://doi.org/10.1016/j.xpro.2021.101074

SUMMARY

Ubiquitin-fold modifier 1 (UFM1) system is a recently identified ubiquitin-like modification with essential biological functions. Similar to ubiquitination, the covalent conjugation of UFM1 (UFMylation) to target proteins involves a three-step enzymatic cascade catalyzed sequentially by UFM1-activating enzyme 5 (UBA5, E1), UFM1-conjugating enzyme 1 (UFC1, E2), and UFM1-specific ligase 1 (UFL1, E3). Here, we provide an optimized protocol adapted to previously reported methods for detecting the UFMylation of target protein in human cells and in vitro assays, respectively, with high reliability and reproducibility.

For complete details on the use and execution of this protocol, please refer to Liu et al. (2020).

BEFORE YOU BEGIN

Preparing high quality plasmid DNAs and HEK293T cells for UFMylation assay in cells, and preparing recombinant proteins of each UFMylation components for UFMylation assay in vitro.

This protocol describes a detailed procedure for UFMylation analysis in cells and in vitro assay. UFMylation is a recently identified ubiquitin-like modification, which covalently conjugates the ubiquitin-like protein UFM1 to target proteins through a three-step enzymatic cascade catalyzed sequentially by UFM1-activating enzyme 5 (UBA5, E1), UFM1-conjugating enzyme 1 (UFC1, E2), UFM1-specific ligase 1 (UFL1, E3) and cofactor DDRGK1 (Komatsu et al., 2004; Gerakis et al., 2019). For UFMylation assay in human cells, we transiently transfect the expression plasmids of UFMylation component (E1, E2, E3, DDRGK1 and UFM1) and the Flag-tagged substrate protein (FLAG-p53) into HEK293T cells, followed by immunoprecipitation with Flag beads and immunoblotting to detect the UFMylated protein with the UFM1 antibody. For in vitro UFMylation assay, we reconstitute UFMylation reaction system with the purified UFMylation components in vitro, followed by immunoblotting to detect the UFMylated protein.

Endotoxin-free plasmids

© Timing: 2 days

Preparation of plasmid DNAs for UFMylation assay in cells. HA-tagged UFMylation component expression plasmids (pSG5-HA-UFM1, pSG5-HA-UFM1-ΔC2, pSG5-HA-UFM1-ΔC3, pSG5-HA-UBA5,
pSG5-HA-UFC1, pSG5-HA-UFL1, pSG5-HA-DDRGK1, and pSG5-HA-vector) and FLAG-tagged substrate expression plasmid (pCDNA3.0-FLAG-His-p53 and pCDNA3.0-FLAG-His-vector) were prepared from 200 mL E. coli which had been cultured for 10–12 h by using Endotoxin-free plasmids kit (TIANGEN). The concentrations of plasmids were measured by NanoDrop One spectrophotometer (Thermo Fisher). Plasmids can be stored at −20°C in small aliquots.

HEK293T cell seeding and cell passage

© Timing: 2–3 days

1. Put 1–2 vials from liquid nitrogen in a 37°C water bath with shaking until completely defrosted.
2. Transfer thawed cells into a 15 mL sterile conical tube prefilled with 4 mL complete DMEM (DMEM supplemented with 10% fetal bovine serum, 1% L-glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin), and centrifuge at 150 × g for 3 min, then carefully aspirate supernatant by a vacuum pump.
3. Re-suspended cells in a total 10 mL fresh complete DMEM in a 10 cm dish and culture in a 37°C incubator with a humidified atmosphere of 5% CO2.
4. HEK293T cells are typically passaged when 80%–90% confluent to a ratio of 1:4.

Cell preparation

© Timing: 4–5 days

5. Aspirate the culture medium and add 5–10 mL of sterile PBS to rinse the cells.
6. Aspirate the PBS and add 1 mL Trypsin EDTA solution A (0.25%) to detach cells in the cell incubator at 37°C.
7. Add 5 mL of complete DMEM and resuspend the cells. Collect the cell suspension in a 15 mL conical tube.
8. Centrifuge at 150 × g for 3 min, then carefully aspirate supernatant by a vacuum pump.
9. Resuspend cells in 40 mL complete DMEM and divide evenly into four 10 cm diameter plates.

Note: One 10 cm-dish with 90%–100% confluent HEK293T cells provides sufficient cells for one sample UFMylation detection. Therefore, the amount of 10 cm dishes should be calculated according to the experiment plan. Before transfection, expand sufficient amounts of HEK293T cells.

Preparation of recombinant protein for UFMylation assay in vitro

© Timing: 5 days

Note: Most recombinant proteins for UFMylation assay in vitro are commercially available, we have prepared in house recombinant UFL1 and DDRGK1 from E.coli, other components (UBA5, UFC1, UFM1, the substrate p53) were purchased from R&D Systems.

10. Culture BL21 (DE3) E. coli cells harboring the pGEX-6P-1-DDRGK1 or pGEX-6P-1-UFL1 plasmid in 1 L LB at 37°C for 3–5 h with rotation at 220 rpm to a cell density (OD600) of 0.6.
11. Add 5 mL IPTG (100 mM) into the E. coli culture medium to final concentration of 0.5 mM with shaking at 19°C for 16–18 h.
12. Transfer E. coli culture to 200 mL centrifuge tubes and spin at 8,000 × g for 5 min at 4°C, then discard the supernatants carefully.
13. Resuspend the cell pellet in 50 mL pre-cold PBS with 1 × protease inhibitor cocktail (Roche) and 1 mM PMSF.
14. Extract protein by breaking bacterial cells using cell disrupter at high pressure for 2–3 cycles.
15. Centrifuge the crude lysate at 14,000×g for 30 min at 4°C.
16. Equilibrate the GST Sepharose gravity column (1 mL) with 5 mL (5 column volume, 5CV) pre-cold 1× PBS with 0.5% TritonX-100 (PBS-X).
17. Load an approximate 50 mL of supernatant (collected from step f) onto the GST Sepharose gravity column.
18. Wash the column with 15 CV PBS-X.
19. Drain the column by gravity and incubate the column with 1 mL PBS-X containing PreScission Protease at 4°C for 16 h.
20. Collect the column flow-through, add glycerol to 20% final concentration, aliquot and store at −80°C.

Note: All the recombinant proteins required for reconstitution of UFMylation in vitro assay are currently commercially available (see the key resources table).

Preparation of polyethyleneimine (PEI) solution

© Timing: 4 h

PEI, a synthetic cationic polymer, can complex with negatively charged macromolecules such as nucleic acids to form small particles capable of gene transfection into various cell lines.

21. Take about 450 mL distilled and sterilized water into a 500 mL glass beaker.
22. Dissolve 500 mg of PEI in the water while stirring.
23. Add approximately 1 mL concentrated HCl (12 M) with a plastic dropper into the solution to bring pH <2.0.
24. Stir for 2–3 h until the PEI is fully dissolved.
25. Add 1–2 mL NaOH (3 M) stock buffer with a plastic dropper into the solution to bring pH 7.0.
26. Add the solution into a 500 mL glass cylinder. Adjust the final volume to 500 mL with above water.
27. Sterile filter the solution through 0.22 μm membrane using a sterile 20 mL syringe.
28. Aliquot PEI in 1 mL/1.5 mL EP tubes and store at −20°C.

CRITICAL: The concentrated hydrochloric acid is an irritating and toxic fume that causes severe respiratory irritation. Similarly, NaOH solution may cause skin and eyes irritation. Personal protective equipment is required.

Polyethyleneimine (PEI) transfection solution

| Reagent      | Final concentration | Amount      |
|--------------|---------------------|-------------|
| Polyethyleneimine | 1 mg/mL            | 100 mg      |
| HCl (12 M)   | N/A                 | Require     |
| NaOH (3 M)   | N/A                 | Require     |
| ddH2O        | N/A                 | Up to 100 mL|
| Total        | N/A                 | 100 mL      |

Note: The PEI solution can be stored at −20°C for up to one year. We recommend using the PEI solution for HEK293T cell transfection. The protocol for the PEI transfection solution was from Cold Spring Harbor Protocol (http://cshprotocols.cshlp.org/content/2008/3/pdb.rec11323.full).
### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| Antibodies          |        |            |
| GAPDH               | HuaAn Biotechnology | M1310-2 |
| FLAG                | Sigma-Aldrich | F7425 |
| HA                  | Cell Signaling Technology | 3724S |
| UFM1                | Abcam    | Ab109305   |
| Anti-Flag M2 Affinity Gel | Sigma-Aldrich | A2220 |
| Goat polyclonal anti-mouse-HRP | Sigma-Aldrich | A9169 |
| Goat polyclonal anti-rabbit-HRP | Sigma-Aldrich | A9044 |
| Anti-p53            | Santa Cruz | sc-126     |
| Bacterial and virus strains |        |            |
| DH5s                | TIANGEN | CB101      |
| BL21 (DE3)          | TIANGEN | CB105      |
| Chemicals, peptides, and recombinant proteins |        |            |
| Dulbecco’s Modified Eagle's Medium(DMEM) | Biological Industries | 06-1055-57-1ACS |
| Fetal Bovine Serum (FBS) | Biological Industries | 04-001-1ACS |
| Trypsin EDTA solution A (0.25%) | Biological Industries | 03-050-1A |
| Opti-MEM™ I Reduced Serum Medium(Opti-MEM) | Gibco | 31985070  |
| Penicillin-Streptomycin | Biological Industries | 03-031-1B |
| Polyethyleneimine (PEI) | Polysciences | 23966 |
| N-Ethylmaleimide (NEM) | Sigma-Aldrich | E3876 |
| Imidazole           | Biosharp | 1-1025     |
| NP40 Alternative    | Sigma-Aldrich | 492016 |
| cOmplete Protease Inhibitor Cocktail Tablets | Roche | 11697498001 |
| Sodium Chloride     | Sigma-Aldrich | 7647-14-5  |
| PMSF                | Roche    | 329-98-6   |
| SDS                 | Sigma-Aldrich | 151-21-3  |
| MgCl₂               | Sigma-Aldrich | 7786-30-3  |
| Recombinant Human His6-UFM1 Activating Enzyme (UBAS) | R&D Systems | E-319-025 |
| Recombinant Human His6-UCF1 Protein (UFC1) | R&D Systems | E2-675-100 |
| Recombinant Human His6-UFM1 Protein (UFM1) | R&D Systems | UL-500-250 |
| p53 Protein         | R&D Systems | SP-454-020 |
| Recombinant Human UFL1 | Abnova | H00023376-P01 |
| Human DDRGK1 protein (Recombinant Myc-DDK (FLAG)) (Full Length) | LSBio | LS-G72211-20 |
| IPTG                | Sigma-Aldrich | 16758 |
| Critical commercial assays |        |            |
| SuperSignal™ West Femto Maximum Sensitivity Substrate | Thermo Fisher Scientific | 34095 |
| ATP (10 mM)         | Cell Signaling Technology | 98045 |
| PreScission protease | Beyotime | P2303 |
| Experimental models: Cell lines |        |            |
| HEK293T cells       | ATCC    | CRL-11268  |
| Recombinant DNA     |        |            |
| pSG5-HA             | Liu et al. (2020) | N/A |
| pSG5-HA-UFM1        | Liu et al. (2020) | N/A |
| pSG5-HA-UFM1-ΔC2    | Liu et al. (2020) | N/A |
| pSG5-HA-UFM1-ΔC3    | Liu et al. (2020) | N/A |
| pSG5-HA-UBAS        | Liu et al. (2020) | N/A |
| pSG5-HA-UFC1        | Liu et al. (2020) | N/A |
| pSG5-HA-UFL1        | Liu et al. (2020) | N/A |
| pSG5-HA-DDRGK1      | Liu et al. (2020) | N/A |
| pCDNA3.0-FLAG-His   | Liu et al. (2020) | N/A |

(Continued on next page)
Key assay buffers and solutions

### Lysis buffer

| Reagent                          | Final concentration | Amount |
|----------------------------------|---------------------|--------|
| pH8.0 Tris-HCl (1 M stock)       | 150 mM              | 15 mL  |
| SDS                              | 5% (w/v)            | 5 g    |
| Glycerol (100% stock)            | 30%                 | 30 mL  |
| ddH₂O                             | N/A                 | 55 mL  |
| Total                            | N/A                 | 100 mL |

**Note:** Store at 20°C–25°C for up to one year.

△ **CRITICAL:** SDS may cause skin and respiratory irritation and should be weighed in the fume hood. Personal protective equipment including rubber gloves and face mask are required.

### Buffer A

| Reagent                          | Final concentration | Amount |
|----------------------------------|---------------------|--------|
| pH8.0 Tris-HCl (1 M stock)       | 50 mM               | 25 mL  |
| NaCl (5 M stock)                 | 150 mM              | 15 mL  |
| Imidazole (2 M)                  | 10 mM               | 2.5 mL |
| NP-40                            | 0.5%                | 2.5 mL |
| 1x protease inhibitor            | N/A                 | N/A    |
| NEM (1 M stock)                  | 2 mM                | 1 mL   |
| ddH₂O                             | N/A                 | 454 mL |
| Total                            | N/A                 | 500 mL |

**Note:** The buffer can be stored at 4°C for up to one year. To minimize degradation of extracted proteins, make sure that protease inhibitor and NEM are freshly added into the buffer A.

**STEP-BY-STEP METHOD DETAILS**

**Assay for UFMylation in cells**

© Timing: 48 h
We have adopted previously reported protocols (Komatsu et al., 2004; Tatsumi et al., 2010; Ishimura et al., 2017) with optimization. In addition, we have included an active (UFM1ΔC2) and defective (UFM1ΔC3) UFM1 for UFMylation detection and data interpretation.

The following steps describe the detailed procedure to efficiently transfect HEK293T with HA-tagged UFMylation component expression plasmids and FLAG-tagged substrate expression plasmid DNAs using PEI transfection solution.

1. Plasmid transfection
   a. HEK293T cells were seeded the night before and transfected with plasmids DNA around 8–10 h later.
   b. In the next morning, transfected cells reached 50%–60% confluency with plasmids using PEI transfection solution. Pre-warm complete DMEM and Opti-MEM in a water bath at 37°C and thaw a fresh aliquot of PEI, HA-tagged UFMylation expression plasmids, FLAG-tagged p53 expression plasmid, and empty vectors in cell culture hood.
   c. Add pre-warmed 500 μL Opti-MEM in the tube A.
   d. Add 54 μL PEI transfection solution in the tube A and mix by gently tipping the tube.
   e. Take HA-tagged expression plasmids of UBA5 (2 μg), UFC1 (2 μg), UFL1 (2 μg), DRGK1 (2 μg), UFM1 (6 μg), and FLAG-tagged p53 expression plasmid (2–6 μg) in a separate tube B.
   f. Add pre-warmed 500 μL Opti-MEM to tube B and mix well by tipping the tube.
   g. Add diluted DNA of tube B to diluted PEI of tube A and mix well.
   h. Incubate for 15 min at 20°C–25°C. Meanwhile, replace the medium with 8 mL fresh complete DMEM medium.
   i. Add the DNA-PEI complex dropwise to cells and gently rotate the dish to mix the transfection mix and medium. Return plates to the incubator.
   j. At 6–8 h after transfection, gently aspirate the culture medium and add 15 mL fresh complete DMEM to each 10 cm dish.
   k. Harvest cells 48 h after transfection.

   **Note:** The optimized amounts, ratios of reagents, and plasmids were listed. For different target proteins, adjust the amount of plasmid DNA that does not exceed 20 μg in total. PEI transfection solution is used for high efficiency transfection in HEK293T cells. However, alternative transfection approaches including calcium phosphate transfection or lentivirus mediated gene delivery may be considered.

2. Cell collection, lysis and immunoprecipitation

   | Tube A | Tube B |
   |--------|--------|
   | Reagents | Amount | Reagents | Amount | Ratios of DNAs |
   | pSG5-HA-UBA5 | 2 μg | pSG5-HA-UBA5 | 2 μg | 1 |
   | pSG5-HA-UFC1 | 2 μg | pSG5-HA-UFC1 | 2 μg | 1 |
   | pSG5-HA-UFL1 | 2 μg | pSG5-HA-UFL1 | 2 μg | 1 |
   | pSG5-HA-DDRGK1 | 2 μg | pSG5-HA-DDRGK1 | 2 μg | 1 |
   | pSG5-HA-UFM1 | 6 μg | pSG5-HA-UFM1 | 6 μg | 3 |
   | pCDNA-FLAG-His-p53 | 2–6 μg | pCDNA-FLAG-His-p53 | 2–6 μg | 1–3 |
   | Opti-MEM | 500 μL | Opti-MEM | 500 μL | |

Step 2. Mix diluted DNA of tube B to diluted PEI of tube A

   **Note:** Pre-warm the complete DMEM and Opti-MEM with a 37°C water bath. Pre-thaw PEI transfection solution and plasmids in cell culture hood and avoid repeated freeze-thaw cycles.
Timing: 14–16 h

a. Aspirate culture medium and gently rinse cells once with 6 mL PBS. Aspirate the PBS and thoroughly remove the residual liquid.

b. Add 400 μL lysis buffer dropwise to cells, collect cells using a plastic scraper and transfer them into a 1.5 mL EP tube.

c. Lyse cells by boiling for 7–10 min at 100°C, then centrifuge at 14,000×g for 1 min at 20°C–25°C to collect the supernatant.

d. Add 900 μL Buffer A into the supernatant and mix well by vortex for 10 s.

e. Centrifuge at 14,000×g for 20 min at 4°C.

f. Take out 80 μL supernatant (collected from step e) of each sample as input, and transfer the rest to a 15 mL conical centrifugal tube which is pre-filled with 8 mL ice-cold buffer A.

g. Add pre-washed beads evenly into the above 15 mL tube and vortex with a rotator at 4°C for 10–12 h.

h. Add 1× SDS loading dye to the input and boil for 10 min at 100°C, then store at −20°C freezer for use.

i. In the next morning, Spin down the overnight incubated beads at 800×g at 4°C for 5 min and aspirate the supernatant.

j. Add 10 mL pre-cold buffer A into the 15 mL tube and mix by tapping, then centrifuge at 800×g at 4°C for 5 min. Then, discard the supernatant carefully and repeat the wash step 5 times.

k. Add 160 μL of 2× SDS loading buffer into beads for each sample and mix well, boiling for 10 min at 100°C.

l. Centrifuge at 14,000×g for 2 min at 20°C–25°C and transfer approximate 160 μL of supernatant to a new 1.5 mL EP tube as IP sample, then store at −20°C freezer.

m. Preparation of Anti-Flag M2 Affinity Gel during the period of the centrifuge (step e) as following:

   i. Vortex beads stock solution thoroughly for 30 s to make a homogeneous slurry.

   ii. Transfer the beads (30 μL beads/sample) into a 1.5 mL EP tube using a pre-trimmed 200 μL pipette tip.

   iii. Centrifuge at 800×g for 3 min at 4°C, carefully discards the supernatant.

   iv. Add 1 mL buffer A to the tube and mix by tapping and centrifuge at 800×g for 3 min at 4°C, carefully aspirate the supernatant.

   v. Resuspend beads with 1 mL buffer A and put it on ice.

Note: To reduce the loss of beads during the washing steps, we recommend to aspirate most of the supernatant with the vacuum pump, and keep 100–200 μL of liquid at the bottom of the 15 mL tube. Aspirate the residual liquid by 200 μL pipette along the wall of the tube.

3. Detection of UFMylated proteins by immunoblotting

Timing: 24 h

a. Input (5 μL) and IP (20 μL) samples were separated on 10% SDS-PAGE gel and then transferred to 0.22 μM PVDF membrane.

Note: PVDF membranes should be immersed in a methanol bath for 1 min with a shaker for activation of PVDF membrane before transfer of protein samples from SDS-PAGE.

b. The PVDF membranes were blocked by 5 % (w/v) nonfat dry milk for 1 h at 20°C–25°C and incubated with primary antibodies at 4°C on a shaker for 10–12 h.

c. Collect the primary antibodies.
d. Rinse PVDF membranes with 20 mL TBS with 0.1% tween-20 (TBST) for 5 min on a shaker 3 times.
e. Incubate membranes with secondary antibodies for 1 h on a shaker at 20°C–25°C.
f. Rinse PVDF membranes as described above.
g. Prepare fresh ECL solution and incubate PVDF with ECL solution for 30–60 s at 20°C–25°C.
h. Adjust the chemiluminescence signals and record images.

**Note:** For the very weak signals, we recommend that a high sensitivity ECL solution can be used, such as SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Fisher).

### Assay for UFMylation in vitro

© Timing: 2–3 days

A substrate protein can be UFMylated in an in vitro system containing UBA5 (E1), UFC1 (E2), UFL1 (E3), DDRGK1 and UFM1 in the presence of ATP. Here, we describe the detailed procedure we used to determine p53 as a novel substrate of UFMylation.

4. Quantify and adjust the concentration of each component (UBA5, UFC1, DDRGK1, UFL1, and UFM1) with Coomassie brilliant blue (CCB).

**Note:** This in vitro UFMylation procedure was referred to the protocol established by Kanako Tatsumi (Tatsumi et al., 2010). To reconstitute in vitro UFMylation system with all indicated components (including UBA5, UFC1, DDRGK1, UFL1, and UFM1), we quantified the relative concentration of each component using densitometry based on the CCB staining and reconstituted in vitro UFMylation reaction by adding all components at equal amount.

a. Preparation of 12% SDS-PAGE gel.
b. Load each protein separately about 100–300 ng per well.
c. Stain gels with staining solution for 2–4 h and de-stain gels with destaining solution for 2–4 h.
d. Record images and quantify the relative concentrations.
e. Adjust the loading quantities of each component and make a vitro UFMylation reaction with an equal amount of each component.

5. Perform in vitro assay of UFMylation.
   a. Prepare a master mix of in vitro UFMylation reaction in PCR tube as follow:

| Reagent                | Final concentration | Suggested ratios of DNAs | Amount |
|------------------------|---------------------|--------------------------|--------|
| ATP (10 mM)            | 5 mM                | N/A                      | 10 µL  |
| UFL1 (100 ng/µL)       | 5 ng/µL             | 1                        | 1 µL   |
| DDRGK1 (200 ng/µL)     | 5 ng/µL             | 1                        | 0.5 µL |
| UBA5 (250 ng/µL)       | 5 ng/µL             | 1                        | 0.5 µL |
| UFC1 (1 µg/µL)         | 5 ng/µL             | 1                        | 0.2 µL |
| UFM1 (2.5 µg/µL)       | 5 ng/µL             | 1                        | 0.5 µL |
| MgCl2 (100 mM)         | 10 mM               | N/A                      | 2 µL   |
| Substrate protein (700 ng/µL) | 17.5 ng/µL | 3.5                      | 0.5 µL |
| PBS-X                  | N/A                 | N/A                      | 4.8 µL |
| Total                  | N/A                 | N/A                      | 20 µL  |

**Note:** The amount of each component in the table is for one reaction. The amount of substrate protein depends on its concentration based on the CCB staining, and the final volume of each
reaction can be scaled proportionally up by the number of reactions in the experiment. We recommend keeping all reagents in an ice bath during the procedure.

b. Incubate the master mix at 30°C for 90 min.
c. Add 5 μL of 5× Loading buffer and mix well, then boil for 5 min at 100°C.
d. Centrifuge at 14,000 g for 1 min at 20°C–25°C, then store at −20°C freezer.
e. Analysis UFMylation of substrate protein by immunoblot, detected by an antibody of the substrate protein as described above.

**Note:** If substrate (p53) protein was modified by UFM1 successfully, at least two bands will be detected **(Figure 2)**.

**EXPECTED OUTCOMES**
The clear mono-UFMylated p53 can be detected by western blot with anti-UFM1 antibody in our UFMylation assay in cells **(Figure 1)**. While in the in vitro assay, the weak band of mono-UFMylated p53 and the stronger band of non-ufmylated substrate of p53 can be detected by western blot with p53 antibody **(Figure 2)**.

**LIMITATIONS**
Owing to the low frequency of modification in cells for some substrates, its UFMylation modification may be hard to detect **(Gerakis et al., 2019)**. Here, we provided an optimized protocol based on transient overexpression of UFMylation components in cells. Although transient overexpression system is widely used in HEK293T cells for detecting various protein modifications including ubiquitin, ubiquitin like (e.g., SUMO, NEDD8, and UFM1), several factors can affect the transfection efficiency, including the cellular state (e.g., cell morphology, cell adherence, cell density, and passage number), quality of PEI solution and plasmids, and the ratio between plasmids and PEI solution, etc. In addition, PEI solution is a cheap transfection reagent with high efficiency HEK293T cells, but it may be not suitable for transfection of other cell types. Alternative transfection approaches including lipofectamine 3000, lentivirus or adenovirus mediated gene delivery may be considered in other cell types. Moreover, UFMylation system is crucial for ER homeostasis, overexpression of UFMylation components may induce ER stress, autophagy, and ER phagy, which may directly or indirectly affect the UFMylation of target proteins. It’s worth mentioning that transient overexpression of UFMylation components may promote the degradation of the target protein in some cases. Lastly, HA-tag and FLAG-tag may alter targeted protein structure, which may interfere with the covalent binding of UFM1.

For these reasons, it is necessary to validate results from the UFMylation assay in cells with the UFMylation assay in vitro. Additionally, it’s worth mentioning that mass-spectrum analysis should be used to authorize the modification site within the substrate protein from the immunoprecipitation sediment.

**TROUBLESHOOTING**

**Problem 1**
Absent or weak UFMylated proteins were detected from the UFMylation assay in cells (step 3).

**Potential solution**
1) Make sure that the expression plasmids for UFMylation components and substrate were correctly expressed based on the input data from Western blot **(Figure 1 lower panel)**. We recommend agarose gel electrophoresis analysis of all plasmids before each transfection. 2) Include a stronger positive control (e.g., ASC1 **(Yoo et al., 2014)** or RPL26 **(Walczak et al., 2019)**) in the UFMylation assay in cells, which can assess whether the experimental procedure was working. In addition, include UFM1-ΔC2 and UFM1-ΔC3 controls to the experimental design **(Figure 1 upper panel)**. 3) Check
the whole procedure of immunoblotting, make sure the reagents and operations were correctly used. 4) Use UFSP2 knockout HEK293T cells, in which the global UFMylation levels are significantly increased due to deficiency of de-UFMylation activity (Walczak et al., 2019). 5) For the weak immunodetection signals, use a high sensitivity ECL solution (e.g., SuperSignal™ West Femto Maximum Sensitivity Substrate, Thermo Fisher).

Problem 2
The size of UFMylated protein is close to the size of immunoglobulin heavy chains, therefore their signals can be overlapped (step 3).

Potential solution
Use HRP conjugated secondary antibodies (e.g., HRP Monoclonal Antibody, 3A5C6, Thermo Fisher) that detect only the correctly folded primary antibody, but not denatured heavy chains.
Problem 3
UFMylated proteins can be reproducibly detected by the assay in cells, but not in the in vitro assay (step 5).

Potential solution
1) Check the quality (expression and concentration) of each component and substrate protein with CCB staining. 2) The degree and efficiency of UFMylation modification for a given substrate may differ to others, the amount of substrate used in UFMylation assay in vitro can be optimized. 3) Covalent modification requires a suitable ionic environment and energy, the concentrations of MgCl2 and ATP can be optimized. 4) Covalent modification may change the protein structure and disrupt the anti-UFM1 recognition, in this case, it is recommended to use the antibody against substrate and anti-UFM1 antibody in detection of UFMyalted proteins.

Problem 4
HEK293T cell shows cytotoxic effects after transfection (step 1)

Potential solution
1) Make sure the plasmids are endotoxin-free. 2) Use fresh HEK293T cells or check cell variability or contaminations. 3) Reduce the amount of PEI (e.g., adjust the ratio of DNA to PEI from 3:1 to 4:1.). 4) Thaw cryopreserved HEK293T cells.

Problem 5
Unspecific protein band (step 3).

Potential solution
1) Pre-incubate the cell lysate with Anti-Flag M2 Affinity Gel for 0.5–1 h to remove potential unspecific binding proteins to beads. 2) Rinse PVDF membranes thoroughly before chemiluminescence with ECL solution. 3) Block the PVDF membrane with 5% nonfat dry milk for at least 1 h at 20°C–25°C on a shaker.

RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Yu-sheng Cong (yscong@hznu.edu.cn).
Materials availability
Materials are available upon reasonable request.

Data and code availability
This study did not generate unique code.

ACKNOWLEDGMENTS
This work was supported by grants from National Natural Science Foundation of China (31730020) and the Hangzhou Science and Technology Bureau (20182014B01).

AUTHOR CONTRIBUTIONS
J.Z., M.D., X.M., D.G., J.L., and Q.L. performed the experiments. J.Z., M.D., and Y.-S.C. wrote the manuscript. All authors contributed to the manuscript and approved it for publication.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
Gerakis, Y., Quintero, M., Li, H., and Hetz, C. (2019). The UFMylation system in proteostasis and beyond. Trends Cell. Biol. 29, 974–986.

Ishimura, R., Obata, M., Kageyama, S., Daniel, J., Tanaka, K., and Komatsu, M. (2017). A novel approach to assess the ubiquitin-fold modifier 1-system in cells. FEBS Lett. 591, 196–204.

Komatsu, M., Chiba, T., Tatsumi, K., Iemura, S., Tanida, I., Okazaki, N., Ieno, T., Kominami, E., Natsume, T., and Tanaka, K. (2004). A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier. EMBO J. 23, 1977–1986.

Liu, J., Guan, D., Dong, M., Yang, J., Wei, H., Liang, Q., Song, L., Xu, L., Bai, J., Liu, C., et al. (2020). UFMylation maintains tumour suppressor p53 stability by antagonizing its ubiquitination. Nat. Cell. Biol. 22, 1056–1063.

Tatsumi, K., Sou, Y.S., Tada, N., Nakamura, E., Iemura, S., Natsume, T., Kang, S.H., Chung, C.H., Kasahara, M., Kominami, E., et al. (2010). A novel type of E3 ligase for the Ufm1 conjugation system. J. Biol. Chem. 285, 5417–5427.

Walczak, C.P., Leto, D.E., Zhang, L., Riepe, C., Muller, R.Y., DaRosa, P.A., Ingolia, N.T., Elias, J.E., and Kopito, R.R. (2019). Ribosomal protein RPL26 is the principal target of UFMylation. Proc. Natl. Acad. Sci. U S A 116, 1299–1308.

Yoo, H.M., Kang, S.H., Kim, J.Y., Lee, J.E., Seong, M.W., Lee, S.W., Ka, S.H., Sou, Y.S., Komatsu, M., Tanaka, K., et al. (2014). Modification of ASC1 by UFM1 is crucial for ERalpha transactivation and breast cancer development. Mol. Cell. 56, 261–274.